QuantumCell commits $2.2bn on AlzeCure’s Alzheimer’s platform
Less than a year after emerging from stealth, Danish-based QuantumCell has signed a multi-billion-dollar deal to equip its pipeline with…
01 Jul 2026
Sanofi aims for Nexviazyme approval in younger Pompe disease patients
Sanofi’s Nexviazyme (avalglucosidase alfa) could be set for approval in younger children with Pompe disease after the Phase III Baby-COMET trial met its primary endpoint. In the single-arm, open-label study…
01 Jul 2026
Anthropic debuts AI-driven pharma R&D tool, Claude Science
Tech giant Anthropic has extended its foray into the life sciences space with a new artificial intelligence (AI) tool, Claude Science, which the company says could offer as a workbench…
01 Jul 2026
Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown
In another blow to the future market prospects of Amgen’s rare disease therapy, Tavneos (avacopan), the New England Journal of Medicine (NEJM) has retracted the drug’s pivotal study paper. This…
01 Jul 2026
US FDA rejects approval of Unicycive’s kidney disease therapy
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on…
01 Jul 2026
Eli Lilly and Innovent agree Verzenios commercialisation deal in China
Eli Lilly and Company has entered into an agreement with Innovent Biologics for the commercialisation of Verzenios (abemaciclib) in mainland China. Under this agreement, Innovent will handle the marketing, distribution…
30 Jun 2026
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme
Eli Lilly and Regeneron are in the first slate of drugmakers included in a new US scheme to expedite the construction of new pharmaceutical manufacturing facilities. Lilly and Regeneron are…